Leapfrog­ging ri­vals, Roche's Tecen­triq plus chemo nabs PFS end­point in front­line lung can­cer seg­ment

Roche has nabbed the first shot at a front­line in­di­ca­tion for a sig­nif­i­cant share of the all-im­por­tant lung can­cer mar­ket with to­day’s news that their check­point Tecen­triq hit the pri­ma­ry end­point on pro­gres­sion-free sur­vival for squa­mous non-small cell lung can­cer. Some an­a­lysts say that in­di­ca­tion could be worth more than a bil­lion dol­lars a year in added rev­enue.

Re­searchers com­bined Tecen­triq with Abrax­ane-based chemo and com­pared it to chemo in first line pa­tients with ad­vanced NSCLC. At an in­ter­im point the com­bi­na­tion beat out chemo on PFS with a sta­tis­ti­cal­ly sig­nif­i­cant out­come but had yet to show an over­all sur­vival ben­e­fit. In­ves­ti­ga­tors will now keep on track­ing re­sults to see how OS mea­sures out.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER